PCV13

Pneumococcal Conjugate vaccine (PCV)


Pneumococcal is a leading cause of serious illness in children and adults throughout the world. The disease is caused by the pneumococcus, which can attack different parts of the human body. According to the WHO, pneumococcal disease is the leading vaccine-preventable killer of children under five years old in the world. At least one million children die of pneumococcal disease every year, most of them young children in developing countries.


The Pneumococcal Conjugate vaccine (PCV) is indicated to prevent diseases caused by S. pneumonia infection from multiple serotypes. The product primarily is for infant primary immunization and toddler booster immunization.Since the U.S. commenced vaccination programs against this disease, the pneumococcal disease incidence has decreased by 94% in the U.S.


Currently the only Pneumococcal Conjugate vaccine available in China is manufactured by Pfizer (Prevnar). Sinovac, the partner of CanSino filed IND of Pneumococcal Conjugate vaccine to CFDA on March 2011. This conjugated vaccine consists of capsular polysaccharides conjugated to the diphtheria toxoid CRM197, and now we are trying to develop a new version that can also protect the people above age of 50.